Scarica l'app Stockscreener
0.285
3.72%
-0.011
Pre-mercato:
.27
-0.015
-5.26%
Oragenics Inc Borsa (OGEN) Ultime notizie
There is no way Arrowhead Pharmaceuticals Inc (ARWR) can keep these numbers up - SETE News
Views of Wall Street’s Leading Experts on Oragenics Inc - SETE News
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, - GlobeNewswire
Power Nickel’s (TSX.V: PNPN) Hole Delivers “BIG”- Gold Terra (TSX.V: YGT) Developments and Exploration Progress Reported – More Stocks Inside! | FinancialContent Business Page - Financial Content
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
OGEN’s valuation metrics: A comprehensive analysis - US Post News
In the Green: Oragenics Inc (OGEN) Closes at 0.28, Up/Down -2.34 from Previous Day - The Dwinnex
Closing Bell Recap: Merck & Co Inc (MRK) Ends at 90.74, Reflecting a -9.07 Downturn - The Dwinnex
Market Insights: 4D Molecular Therapeutics Inc (FDMT)’s Notable Drop of -0.17, Closing at 5.92 - The Dwinnex
Post-Trade Analysis: Charter Communications Inc (CHTR) Slides -0.36, Closing at 340.26 - The Dwinnex
US Stocks Mixed; Walt Disney Posts Upbeat Earnings - Benzinga India
United Micro Electronics ADR [UMC] Investment Guide: What You Need to Know - Knox Daily
Oragenics Inc (OGEN) may enjoy gains as insiders got busy in the recent days - Knox Daily
The Potential Rise in the Price of Dolby Laboratories Inc (DLB) following insiders activity - Knox Daily
Oragenics Inc Inc. (OGEN) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
PCSO Lotto Results | February 5, 2025 - The Manila Times
Citigroup lifts StoneCo Ltd [STNE] price estimate. Who else is bullish? - The DBT News
Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com - Defense World
Rubicon Technology (NASDAQ:RBCN) Now Covered by StockNews.com - Defense World
BlackRock Long-Term Municipal Advantage Trust (NYSE:BTA) Enters Standstill Agreement with Saba Capital Management, L.P.On January 20, 2025, BlackRock Long-Term Municipal Advantage Trust (NYSE:BTA) disclosed that it, along with BlackRock Advis - Defense World
Credit Suisse Group (NYSE:CS) Now Covered by StockNews.com - Defense World
Dermata Therapeutics Signs Clinical Trial Collaboration Agreement with Revance Therapeutics for Topical Treatment StudyDermata Therapeutics, Inc. (NASDAQ: DRMA) revealed in an 8-K filing that on January 17, 2025, the company entered into a Clinical T - Defense World
Oragenics, Inc. Update: Janet Huffman Appointed Interim CEO - Defense World
Oragenics (OGEN) Stock Price, News & Analysis - MarketBeat
Oragenics gears up for Phase II trials, appoints new CEO By Investing.com - Investing.com Australia
Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO - GlobeNewswire
Oragenics gears up for Phase II trials, appoints new CEO - MSN
Ocean Power Technologies Demonstrates Multi-Day Advanced Remote Survey Capabilities - The Manila Times
Oragenics appoints interim CEO, ups CFO salary By Investing.com - Investing.com Canada
Oragenics appoints interim CEO, ups CFO salary - MSN
Oragenics Announces Leadership Changes and Relocation - TipRanks
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Energy Transfer Rocketed 42% in 2024 - The Globe and Mail
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
XOMA (NASDAQ:XOMA) and Oragenics (NYSE:OGEN) Head to Head Review - Defense World
Cencora Expands Specialty Leadership with $4.4 Billion Acquisition of Retina Consultants of America - MSN
Oragenics (NYSE:OGEN) Now Covered by StockNews.com - Defense World
Anti-Oral Mucositis Drug Market 2025-2032: Revenue Growth, Business Opportunities, Trends and Forecast - WICZ
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics Simplifies Capital Structure and Advances Strategy - TipRanks
Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference - The Manila Times
Oragenics Strengthens Balance Sheet: $2.35M Preferred Share Conversion Streamlines Capital Structure - StockTitan
Oragenics director Alan Dunton sells $23 in common stock By Investing.com - Investing.com Canada
Oragenics director Alan Dunton sells $23 in common stock - Investing.com
Oragenics director Fred Telling sells $1,294 in common stock - Investing.com
Oragenics director Fred Telling sells $1,294 in common stock By Investing.com - Investing.com UK
Certain Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2024. - Marketscreener.com
Certain Warrants of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2024. - Marketscreener.com
Oragenics announces termination of president's employment agreement By Investing.com - Investing.com South Africa
Oragenics announces termination of president's employment agreement - Investing.com India
0.82%
0.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):